Uma Lakshmipathy Email & Phone Number

San Diego, Ca, Us

Waltham, Ma, Us

In my role, I launched and scaled a translational services business, creating GMP-compliant pathways and streamlining workflows to accelerate the transition from research to clinical manufacturing of cell therapies. By implementing rapid development frameworks, I ensured the efficient translation of cutting-edge research into scalable production processes. I drove this transition forward by developing standardized processes and foundational cell characterization assays, aligning strategic roadmaps with emerging market trends and evolving regulatory requirements.I built and led a high-performing team, establishing clear objectives, fostering collaboration, and delivering continuous training to ensure we met and exceeded organizational goals. Through strategic partnerships with leading academic institutions and industry experts, I advanced the development of transformative therapies. My efforts maximized operational efficiency and significantly enhanced our organization's capabilities in cell and gene therapy translation services, positioning us as a key player in the evolving biotech landscape.

Waltham, Ma, Us

During my tenure, I designed and delivered bespoke solutions for clients in viral services, cell engineering, and assay development, enhancing their research capabilities and accelerating project timelines. I pioneered groundbreaking translational initiatives that connected research advancements with practical applications, driving innovation across multiple scientific fields and strengthening core business operations. My proactive leadership and strategic vision resulted in more efficient processes and faster, impactful outcomes, reinforcing the organization’s position at the forefront of scientific innovation.

Waltham, Ma, Us

I led transformative initiatives within the Cell and Gene Therapy Strategic Business Segment, collaborating closely with academic and industry leaders to develop and launch compliant products and tailor-made service solutions. I drove enhancements in evaluating immune cell identity and purity by pioneering advanced characterization assays, such as the PureQuant Methylation Assays and Essential Phenotyping Kits. I also forged strong partnerships across departments to develop cutting-edge roadmaps and product pipelines, integrating innovative analytical tools for characterizing induced pluripotent stem cells (iPSCs) and positioning our team as leaders in regenerative medicine.My strategic vision resulted in creating a multimillion-dollar reprogramming portfolio, highlighted by the successful launch of the CytoTune 2.1 system and the SEV Quantitation Kit, which revolutionized cell therapy and regenerative medicine clinical workflows. I also spearheaded the launch of groundbreaking analytical products—ScoreCard, PluriTest, and KaryoStat—that set new industry standards for assessing iPSC cell banks' quality, pluripotency, and chromosomal integrity. Through these initiatives, I advanced the field of cell and gene therapies and solidified our market leadership in a highly competitive space.

La Jolla, Ca, Us

San Francisco, Us

San Marcos, Ca, Us

Professional Master's degree in BiotechnologyBioT600 - 910, 911A, 912B Genomics & DNA/RNA TechnologyBioT690 Trends in Biotechnology

Holytown, North Lanarkshire, Gb

Waltham, Ma, Us

In my role, I led high-performance teams, overseeing task management, feedback, and personalized development plans to drive individual growth and maximize team efficiency. I integrated cutting-edge RNA and miRNA signatures in stem cell transcriptomics and epigenomics, significantly enhancing research quality and streamlining workflows to accelerate progress. By developing innovative strategies and advancing core technology platforms for stem cell and cell engineering programs, I pushed the boundaries of scientific discovery. I accelerated the application of novel therapeutic solutions.I forged and strengthened global partnerships, presenting groundbreaking research and technologies to internal teams and external stakeholders worldwide, fostering valuable collaborations. Additionally, I made substantial contributions to the scientific community by authoring high-impact review articles and editing influential books on emerging technologies and stem cells, enriching the knowledge base and shaping the future direction of research in these fields.

Conducted original research and studies which led to building new strategic areas and core technology platforms relevant to stem cells and cell engineering program. Played key role in the design and development of integrational and non-integrational cell engineering platforms optimal for stem cells.

Minneapolis, Minnesota, Us

• Proposed and developed non-viral gene transfer in stem cells and published the first seminal paper of efficient delivery of plasmids into human embryonic stem cells.• Utilized homologous recombination in adult stem cells to facilitate ex vivo repair of adult stem cells for autologous transplant in disease models of Fanconi anemia.• Independently supported self and team with grants from Lymphoma Leukemia Society and Fanconi Anemia Society.

Minneapolis And St. Paul, Minnesota, Us

• Studied double strand DNA repair mechanisms via non-homologous DNA end-joining and homologous recombination in mammalian cells.• Identified molecular components and mechanisms involved in the repair and maintenance of mammalian mitochondria.• Supported self via fellowship from American Heart Association.

Structural and functional characterization of corneal proteins using molecular spectroscopyThesis: Structure and confirmation of corneal proteins

Ph.D., Protein Structure And Function

Master Of Science, Biochemistry

Bachelor Of Science, Chemistry And Biology